All News

From 2019 to 2024, GLP-1 prescriptions among pediatric patients with type 2 diabetes increased from 12.3% to 60.9%.

The most frequent barriers to access to glucagon include cost, patient health literacy, and insurance coverage.

Researchers explored the prevalence of obesity-related complications and obesity medication use in US children and young adults with obesity.

The initiative focuses on managing medications for high-risk diabetes patients through a collaborative drug therapy agreement.

Researchers presented an abstract describing current racial disparities in CGM access and wear time to better inform quality improvement efforts.

Thimerosal is a mercury-containing compound that has been widely used as a preservative in some biological and drug products since the 1930s.

Revita is a procedure that modifies duodenal dysfunction and restores metabolic health, according to Fractyl Health.

Taylor Watterson, PharmD, PhD, discusses how distress experienced by pharmacy technicians can impact the overall safety and quality of pharmacy operations.

Pharmaceutical Strategies Group experts joined Drug Topics to discuss the role GLP-1s play in drug benefit design.

This approval offers pediatric patients and caregivers the first subcutaneous option that can be administered at home.

Researchers explored the impact of a $0 copay program on hemoglobin A1c levels in patients with type 2 diabetes who were also insured by Blue Cross and Blue Shield of Louisiana.

In a retrospective study of obesity-related mortality, researchers explored US death trends before, during, and after the COVID-19 pandemic.

Data presented at ADA 2025 showed patients who received outreach from a clinical pharmacist were more likely to be prescribed safer diabetes regimens.

In a real-world, 6-month analysis, glucagon-like peptide-1 programs with obesity telemedicine behavioral programs resulted in benefits to weight loss and blood pressure.

Nicole Cieri-Hutcherson, PharmD, BCPS, MSCP, FCCP, discusses how pharmacists can support patient counseling and education around medication abortion.

Morgan Lee, PhD, MPH, CPH, and Scott Halperin, PharmD, from the Pharmaceutical Strategies Group, discuss how the role of PBMs in plan design is evolving.

When compared with adults 45 years and older, those 18 to 44 years are less likely to receive treatment or achieve target goals for cardiometabolic risk factors.

At the Total Pharmacy Solutions Summit Summer 2025 event, Stephanie Zimmerman, Tom Napolitano, and Luke Gunderson discussed the benefits of Real Value RX.

Kevin Cleveland, PharmD, discusses how pharmacists are uniquely positioned to provide immediate, direct interactions with patients, making them vital in addressing vaccine misinformation.

Investigators assessed continuous glucose monitoring with behavioral intervention for patients with type 1 diabetes.

Data presented at ADA’s 85th Scientific Sessions showed patients who received physician education with clinical pharmacist outreach had significantly better A1c levels at 6 months compared to usual care.

Tara Pfund, PharmD, chief strategy officer with the Cascadia Pharmacy Group, discusses a variety of ways community pharmacists can expand services and support clinical reimbursement.

Abstract researchers explored whether or not a pharmacist could serve as the lead of a diabetes coaching program, aiming to reduce medical expenditures and A1C levels for at-risk patients.

Heidi Polek, RPh, EMBA, discusses how pharmacies must adopt strategic approaches to maintain financial health and continue providing patient care.

Emily Endres, BSPS, and Todd Sega, PharmD, MBA, discuss pressures that pharmacies are currently facing, including reimbursements, competition, and patient needs.

Taylor Watterson, PharmD, PhD, discusses several different ways pharmacy technician contributions can be better recognized and appreciated.

Nicole Cieri-Hutcherson, PharmD, BCPS, MSCP, FCCP, discusses how pharmacist involvement in medication abortion can improve reproductive health care access.

John Hill, MBAHCM, and Pooja Babbrah, MBA, from the National Council for Prescription Drug Programs, discuss their organization’s strategic plan for advancing the pharmacy profession.

Check out our coverage from the American Pharmacists Association Annual Meeting and Exposition 2025!

Morgan Lee, PhD, MPH, CPH, and Scott Halperin, PharmD, from the Pharmaceutical Strategies Group, discuss the 2025 Trends in Drug Benefit Design Report and how it will impact pharmacists.